Abstract 1905P
Background
Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that form postnatally in non-lymphoid tissues and arise under physiological conditions. However, the clinical and immunological implications of heterogeneous subpopulations of TLS in clear cell renal cell carcinoma (ccRCC) remain to be elucidated.
Methods
H&E, immunohistochemistry and 12-marker multispectral fluorescent were used to evaluate the spatial location and maturation status of TLS with TME cell-infiltrating characterizations. We comprehensively assessed the prognostic value of TLS heterogeneity in 395 patients with ccRCC from two independent cohorts using log-rank tests, Cox hazards models, and scoring nomograms. Associations between TLS heterogeneity and immunologic activity of TME were assessed using quantified lymphocytes infiltration fraction.
Results
By pathological review, TLS were identified in 34.2% of the ccRCC samples. For ccRCC patients, the presence of intratumoral TLS markedly correlated with both superior progression-free survival (PFS) and overall survival (OS), while the peritumoral TLS exerted the opposite predictive trend of clinical outcomes. Multivariate Cox analysis revealed that the presence of intratumoral TLS was prominently correlated with better outcomes. Additionally, the novel nomograms incorporating the presence of intratumoral TLS prominently predicted the probability of 8-year PFS and OS of ccRCC (AUC >0.80). Moreover, a higher proportion of early TLS was found in peritumoral TLS (P=0.016), while intratumoral TLS were mainly composed of secondary follicle-like TLS (P=0.004). Interestingly, in ccRCC samples with the presence of peritumoral TLS enriched with primary follicle-like TLS, the proportion of PD-L1+ tumor-associated macrophages and Treg infiltration in the stroma were prominently increased, showing a typical suppressive tumor immune microenvironment.
Conclusions
In conclusion, this study revealed the predictive value of TLS heterogeneity on the progression and immunological responses of ccRCC for the first time. The intratumoral TLS could be used to assess both the prognostic patterns and the unique TME characteristics of each patient.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1726P - Optimizing oncology drug spending in a cancer centre in Ireland
Presenter: Ruth Kieran
Session: Poster session 23
1727P - Barriers and facilitators of physician involvement in clinical oncology database management in Ukraine
Presenter: Inesa Huivaniuk
Session: Poster session 23
1728P - Implementation of a comprehensive oncology unit: Needs detected in cancer survivors during follow-up
Presenter: Francisco J Jimenez-ruiz
Session: Poster session 23
1729P - Targeted interventions in registration and reporting of multidisciplinary team meetings (MDT) in oncology help to improve tumor board decisions
Presenter: Lars Galonska
Session: Poster session 23
1730P - Dealing with digital paralysis: Surviving a cyberattack in a cancer centre
Presenter: Rachel J. Keogh
Session: Poster session 23
1731P - Providing access to anticancer drugs within an armed conflict: The experience of Mission Kharkiv (MK) and Medecins Sans Frontieres (MSF) in Ukraine
Presenter: Stanislav Polozov
Session: Poster session 23
1732P - War and the fragility of anticancer drug supply networks in Ukraine
Presenter: Olha Kostenchak-Svystak
Session: Poster session 23
1733P - Two wars at time: Fight against cancer during war time - experience of Ukraine
Presenter: Veronika Patsko
Session: Poster session 23
1734P - Early impact of a personalized lung cancer interception program for heavy smokers
Presenter: Pamela Abdayem
Session: Poster session 23
1735P - Impact of revised US Preventive Services Task Force (USPSTF) 2021 lung cancer screening guideline on long-term cancer survivors in the United States
Presenter: Qian Wang
Session: Poster session 23